Elliott M - Search Results

1

Improved pharmaceutical stability of a boronphenylalanine mannitol formulation for boron neutron capture therapy.

Halbert G, Elliott M, Ford S, Dick L, Schmidt E. Halbert G, et al. Among authors: elliott m. Eur J Pharm Sci. 2013 Mar 12;48(4-5):735-9. doi: 10.1016/j.ejps.2013.01.008. Epub 2013 Jan 23. Eur J Pharm Sci. 2013. PMID: 23354152

2

Physicochemical investigation of the influence of saccharide-based parenteral formulation excipients on L-p-boronphenylalanine solubilisation for boron neutron capture therapy.

Schmidt E, Dooley N, Ford SJ, Elliott M, Halbert GW. Schmidt E, et al. Among authors: elliott m. J Pharm Sci. 2012 Jan;101(1):223-32. doi: 10.1002/jps.22761. Epub 2011 Sep 14. J Pharm Sci. 2012. PMID: 21918989 Free article.

3

Boron phenylalanine and related impurities: HPLC analysis, stability profile and degradation pathways.

Dick L, Dooley N, Elliott MA, Ford SJ, Gordon MR, Halbert GW, Kerr WJ. Dick L, et al. J Pharm Biomed Anal. 2011 Nov 1;56(3):633-6. doi: 10.1016/j.jpba.2011.06.025. Epub 2011 Jul 1. J Pharm Biomed Anal. 2011. PMID: 21775086

4

Development of a lyophilised RH1 formulation: a novel DT diaphorase activated alkylating agent.

Elliott MA, Ford SJ, Walker AA, Hargreaves RH, Halbert GW. Elliott MA, et al. J Pharm Pharmacol. 2002 Apr;54(4):487-92. doi: 10.1211/0022357021778754. J Pharm Pharmacol. 2002. PMID: 11999125

5

Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial.

Elliott MA, Ford SJ, Prasad E, Dick LJ, Farmer H, Hogg PJ, Halbert GW. Elliott MA, et al. Int J Pharm. 2012 Apr 15;426(1-2):67-75. doi: 10.1016/j.ijpharm.2012.01.024. Epub 2012 Jan 21. Int J Pharm. 2012. PMID: 22286018 Clinical Trial.

6

Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing.

Dick LJ, Gray A, Ram A, Hume A, Parris C, Hogg PJ, Elliott MA, Ford SJ, Halbert GW. Dick LJ, et al. J Pharm Pharmacol. 2013 Nov;65(11):1664-9. doi: 10.1111/jphp.12143. Epub 2013 Sep 18. J Pharm Pharmacol. 2013. PMID: 24102542 Free PMC article.

7

Determination of excipient based solubility increases using the CheqSol method.

Etherson K, Halbert G, Elliott M. Etherson K, et al. Among authors: elliott m. Int J Pharm. 2014 Apr 25;465(1-2):202-9. doi: 10.1016/j.ijpharm.2014.02.007. Epub 2014 Feb 7. Int J Pharm. 2014. PMID: 24513529

8

Use of mathematical derivatives (time-domain differentiation) on chromatographic data to enhance the detection and quantification of an unknown 'rider' peak.

Ford SJ, Elliott MA, Halbert GW. Ford SJ, et al. Among authors: elliott ma. J Pharm Biomed Anal. 2003 Nov 24;33(4):563-70. doi: 10.1016/s0731-7085(03)00354-6. J Pharm Biomed Anal. 2003. PMID: 14623581

9

Maintaining a frozen shipping environment for Phase I clinical trial distribution.

Elliott MA, Halbert GW. Elliott MA, et al. Int J Pharm. 2008 Jan 4;346(1-2):89-92. doi: 10.1016/j.ijpharm.2007.06.008. Epub 2007 Jun 14. Int J Pharm. 2008. PMID: 17629640 Free article.

10

The influence of non-ionisable excipients on precipitation parameters measured using the CheqSol method.

Etherson K, Halbert G, Elliott M. Etherson K, et al. Among authors: elliott m. J Pharm Pharmacol. 2016 Sep;68(9):1131-42. doi: 10.1111/jphp.12602. Epub 2016 Jul 1. J Pharm Pharmacol. 2016. PMID: 27367258 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,241 results

Search Page

Filters